Live- In Person Washington, DC, Meeting

1.5 CME/NCPD Credit
Click Here to complete the pre-assessment

Activity Description

Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.

Don’t miss this opportunity to compete with and against your peers for prizes as you expand your knowledge and elevate your ability to provide holistic, evidence-based care, facilitate the smooth integration of CAR T-cell therapies in diverse clinical settings, and ultimately optimize patient outcomes

This activity is intended for academic and community nurses and NPs who treat and manage patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

After completing this CE activity, the participant should be better able to:

  • Describe the process of CAR T-cell therapy, including its manufacturing, administration, and mechanism of action in NHL and MM
  • Align CAR T-cell therapy choices and new and emerging treatments, including bispecific antibodies and combination therapies (e.g., TCEs and CELMoD) with NCCN clinical guidelines, by incorporating the latest clinical evidence, drug mechanism of action, patient preferences, and disease subtypes for both NHL and MM
  • Employ effective patient education in differentiating available treatment options, addressing clinical trial participation, and providing resources for patient/caregiver support
  • Integrate strategies to identify and manage common treatment-emergent events and long-term toxicities related to CAR T-cell therapy
  • Incorporate action-based plans to address challenges associated with transitioning CAR T-cell therapy to community practices and outpatient settings, thereby improving patient access

Joint Accreditation with Commendation Logo In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hours in the area of pharmacology.

Supporter

This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Inc.

Pre-Assessment

Please enable JavaScript in your browser to complete this form.
1. A 65-year-old female patient with R/R NHL is considering CAR T-cell therapy with brexucabtagene autoleucel as a potential treatment option. In discussing the unique features of CAR T therapy, which of the following statements accurately reflects a key consideration for patient selection?
2. What is the mechanism of action of CAR T-cells against cancer?
3. A 50-year-old male patient with R/R MM is scheduled to undergo CAR T-cell therapy with ciltacabtagene autoleucel. He is curious about the process of generating CAR T-cells and asks for more information. How would you explain this to the patient?
4. How does CAR T therapy differ from traditional chemotherapy?
5. According to NCCN guidelines, what is the primary consideration to determine a patient’s suitability for CAR T therapy?
6. According to regulatory guidelines, how long should patients be monitored post-CAR T therapy infusion?
7. A 45-year-old female patient with MM presents for a follow-up appointment. She now has relapsed/refractory MM after receiving an iMiD, PI, and anti CD38Ab. Which of the following treatments is the most appropriate?
8. How do NCCN guidelines suggest monitoring long-term outcomes after CAR T therapy?
9. A 68-year-old male patient presents to the oncology clinic with a diagnosis of R/R MM. He has a history of hypertension and mild renal impairment and is being considered for CAR T-cell therapy. Based on this scenario, which of the following would make a patient ineligible for idecabtagene vicleucel or ciltacabtagene autoleucel?
10. A 65-year-old male patient with a history of relapsed/refractory NHL calls your community clinic saying he thinks he is experiencing confusion and delirium. He received CAR T-cell therapy with lisocantagene maraleucel 4-5 days ago. What do you suspect is most likely happening?
11. A 55-year-old female patient with R/R MM undergoes CAR T-cell therapy with idecabtagene vicleucel. Three days post-treatment, she develops high fever, hypotension, and respiratory distress. In addition to supportive care, which intervention would you do next?
12. What can help assure a smooth transition from a CAR T center to a community center following CAR T-cell therapy?
Go to Event Site
Scroll to Top